GlassScriptPhysician profile
Jones Trevor Nauseef
NPI 1023403839
$16,761.21
in general payments reported to CMS, 2019-2025
10 companies · $259 in 2025
The $259 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.72 · 2021: $212 · 2022: $121 · 2023: $15K · 2024: $680 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,174 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,790 · Food and Beverage: $2,019 · Travel and Lodging: $1,346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,174.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,790.00 |
| Food and Beverage | $2,019.33 |
| Travel and Lodging | $1,346.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $15,291.13 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $897.60 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $139.70 | 2023-2024 | Libtayo |
| Myovant Sciences INC. | $97.42 | 2022 | |
| Genzyme Corporation | $95.85 | 2023 | |
| Sanofi-Aventis U.S. LLC | $74.99 | 2019 | |
| Janssen Biotech, INC. | $71.26 | 2023 | Balversa, Erleada |
| Sumitomo Pharma America, INC. | $48.52 | 2023 | Orgovyx |
| Celgene Corporation | $23.73 | 2019 | |
| Aveo Pharmaceuticals, INC. | $21.01 | 2023 | Fotivda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jones Nauseef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.